Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Assess the Efficacy and Safety of Filgotinib Administered for 16 Weeks to Subjects With Moderately to Severely Active Psoriatic Arthritis

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Assess the Efficacy and Safety of Filgotinib Administered for 16 Weeks to Subjects With Moderately to Severely Active Psoriatic Arthritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms EQUATOR
  • Sponsors Galapagos NV
  • Most Recent Events

    • 09 Nov 2021 Results of whole-blood RNA-Seq data analysis evaluatingthe impact of Filgotinib on gene expression and biological pathways, presented at the ACR Convergence 2021
    • 05 Jun 2021 Results of a post-hoc analysis from EQUATOR and EQUATOR 2 (up to OLE week 100) assessing effect of Filgotinib on individual PASDAS socre components and association between PASDAS disease activity levels presented at the 22nd Annual Congress of the European League Against Rheumatism
    • 05 Jun 2021 Results post-hoc analysis from clinical studies: EQUATOR and EQUATOR 2 assessing patient-level correlation between changes over time in three PsA clinical disease domains of skin, joint and enthesitis presented at the 22nd Annual Congress of the European League Against Rheumatism
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top